Journal
BIOMEDICINES
Volume 10, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10010001
Keywords
temozolomide; glioblastoma; pharmacology; site of action; quantification; omics
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [404521405, SFB 1389-UNITE]
- UNITE Innovation Fund 2020
Ask authors/readers for more resources
This article summarizes the ADME parameters and modes of action of Temozolomide (TMZ), and provides methodological options to monitor TMZ at its anatomical, cellular, and molecular sites of action (SOAs). The focus is on mass spectrometry-based approaches, with considerations given to avoiding artifacts in the analysis.
Temozolomide (TMZ), together with bulk resection and focal radiotherapy, is currently a standard of care for glioblastoma. Absorption, distribution, metabolism, and excretion (ADME) parameters, together with the mode of action of TMZ, make its biochemical and biological action difficult to understand. Accurate understanding of the mode of action of TMZ and the monitoring of TMZ at its anatomical, cellular, and molecular sites of action (SOAs) would greatly benefit precision medicine and the development of novel therapeutic approaches in combination with TMZ. In the present perspective article, we summarize the known ADME parameters and modes of action of TMZ, and we review the possible methodological options to monitor TMZ at its SOAs. We focus our descriptions of methodologies on mass spectrometry-based approaches, and all related considerations are taken into account regarding the avoidance of artifacts in mass spectrometric analysis during sampling, sample preparation, and the evaluation of results. Finally, we provide an overview of potential applications for precision medicine and drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available